Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study
Article first published online: 19 NOV 2012
© 2012 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 37, Issue 2, pages 252–262, January 2013
How to Cite
Kelly, C. P., Green, P. H. R., Murray, J. A., DiMarino, A., Colatrella, A., Leffler, D. A., Alexander, T., Arsenescu, R., Leon, F., Jiang, J. G., Arterburn, L. A., Paterson, B. M., Fedorak, R. N. and the Larazotide Acetate Celiac Disease Study Group (2013), Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Alimentary Pharmacology & Therapeutics, 37: 252–262. doi: 10.1111/apt.12147
- Issue published online: 17 DEC 2012
- Article first published online: 19 NOV 2012
- Manuscript Accepted: 29 OCT 2012
- Manuscript Revised: 28 OCT 2012
- Manuscript Revised: 19 OCT 2012
- Manuscript Received: 11 SEP 2012
- Alba Therapeutics Corporation
- Cephalon, Inc.
Table S1. Mean change from baseline in gastrointestinal symptoms as rated by the Gastrointestinal Symptoms Rating Scale (GSRS).
Figure S1. Exploratory binary analysis. Proportions of patients who responded to the gluten challenge, as indicated by an anti-tTG score ≥15 U/mL or an increase of ≥0.3 units in the CeD-GSRS symptom score (or both) at the end of the treatment period in the placebo and active treatment groups.
Figure S2. Psychological General Well-Being Index scores for anxiety (a), depressed mood (b), positive well-being (c), self-control (d), general health (e), and vitality (f) domains and the global score (g).
Figure S3. Changes from baseline (day 7) to the last double-blind treatment period visit in clinician global assessment scores.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.